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Single tube single-color analysis of rifampicin
and isoniazid allelic variants in MDR-TB
L. Wangh ∗, J. Rice, K. Pierce
Brandeis University, Waltham, MA, USA
Background: We have constructed a highly informative, rapid,
single-tube, single-color assay for distinguishing variants in the
inhA promotor, and katG and rpoB gene targets responsible for iso-
niazid and rifampicin resistance, using technologies invented at
Brandeis University.
Methods & Materials: Amultiplex LATE-PCR reaction is used to
generate single-stranded DNA products for the Rifampicin Resis-
tance Determining Region of the rpoB gene, the katG gene, and the
inhA promotor, as well as an ampliﬁable internal control. These
four amplicons are detected with four sets of Therma-Light probes
all of which are labeled with Black Hole Quenchers with/without
Quasar 670 ﬂuorophors. Probe-target hybridization takes place at
end-point over a wide range of temperatures below the reaction
annealing temperature. The temperature ranges used for the four
sets of Therma-Light probes are deliberately overlapped, making it
possible tomaximize the amount of information generated in a sin-
gle color. The ampliﬁable internal control generates a speciﬁc very
low temperature signal and an additional non-ampliﬁable internal
control generates a second signal at a speciﬁc high temperature.
Together these controls can be used to calibrate each reaction.
Another proprietary reagent is added to the reaction mixture to
improve primer speciﬁcity.
Results: The present assay has been tested on twenty-two
different archival strains which are reported to harbor many
of the common alleles responsible for resistance to rifampin
and isoniazid. Each strain displayed its own “ﬂuorescent sig-
nature” reﬂecting the underlying alleles present in the three
target sequences. But, not every ﬂuorescent signature agreed with
archival information on the mutational composition of the strain.
These discrepancies were resolved by sequencing the reaction
products. The results show that the ﬂuorescent signatures con-
sistently identify the alleles correctly. Many more strains of M.
tuberculosis will soon be tested.
Conclusion: This single color multiplex assay has both clinical
and researchapplications and is just oneofmanypossible assays for
M(X)DR-TB that can be constructed using these technologies. For
instance, Therma-Light probes labeled with ﬂuorophores in other
colors can be added for simultaneous analysis variants responsible
for resistance to all other ﬁrst and second line antibiotics.
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Evaluating a minipool strategy to screen for
virologic failure and antiretroviral drug
resistance
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Background: For patients on antiretroviral treatment (ART),
monitoring of HIV viral load is superior to clinical monitoring
alone or clinical combined with CD4 count monitoring. How-
ever, the high cost of commercial viral load tests limits its use in
resource-constrained settings. Commercial genotypic antiretrovi-
ral resistance testing is even more costly, yet it provides important
additional information. Information on the presence of drug resis-
tance mutations allows for an informed decision to be made
regarding switching to second-line ART and which drugs to switch
to, all of which could save money and improve patient outcomes.
The novel strategy presented here, consisting of pooled testing by
qualitative PCR with a deﬁned threshold and limited sequencing
of positive samples, provides a potential solution to this problem,
allowing for cheaper, more efﬁcient monitoring of patients on ART
in resource-limited settings.
Methods & Materials: A total of 300 routine patient samples
were included and tested in 60 pools of 5 samples each. A qualita-
tive nested PCR using previously described primers was optimised
for testing pools and individual samples from positive pools. All
positive samples were tested for drug resistance-associated muta-
tions. The results obtained by conventional viral load monitoring
and by the pooling algorithm were compared.
Results: Twenty-two of sixty pools tested positive. Deconvo-
lution of the positive pools yielded 29 positive individual samples.
Twenty-six patients had viral loads of above 1000 copies per
milliliter and were therefore failing therapy according to national
criteria. The pooling algorithm detected 24 of those 26 patients,
resulting in a negative predictive value of 99.3%. The sensitivity for
detecting patients failing therapy was 92%. The commonest NRTI
mutations were M184V/I and K65R, with 7% and 2%, respectively,
of the studypopulationharboring thesemutations. The commonest
NNRTI mutation was K103N.
Conclusion: The pooled testing algorithm presented here was
able to detect 24 of 26 adult patients failing ﬁrst-line ART, and
required 43% fewer assays than conventional viral load testing.
In addition it provided drug resistance information, which is not
routinely available in resourced-limited settings, and yielded a
potential cost saving over individual viral load testing.
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